The efficacy and safety of liver rehabilitation for patients with chronic liver disease: a prospective clinical trial.

Shimizu Masahito0 个研究点目标入组 45 人开始时间: 2023年9月6日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients aged 20 or older
•2. Patients diagnosed with chronic hepatitis, cirrhosis, or liver cancer by histological or clinical criteria (regardless of etiology)
•3. Patients with exercise tolerance

•1. Patients with reduced liver reserve function (Child-Pugh class C and/or MELD score 20 or higher)
•2. Patients with esophageal-gastric varices that require treatment
•3. Patients with hepatic encephalopathy
•4. Patients with refractory ascites
•5. Anemia or thrombocytopenia
•6. Mental or physical disabilities that prevent safe exercise therapy
•7. Uncontrolled systemic diseases (infections, electrolyte abnormalities, thyroid dysfunction, etc.)
•8. Signs or symptoms (chest discomfort, dyspnea, dizziness, syncope, palpitations, heart murmur, etc.) during exertion
•9. Past or present medical conditions (history of myocardial infarction, pacemaker/implantable cardioverter-defibrillator/rhythm disorder, valvular heart disease, heart failure, heart transplant, congenital heart disease)
•10 Heart rate (>100 mmHg or <50 mmHg), systolic blood pressure (>160 mmHg or <85 mmHg), diastolic blood pressure (>110 mmHg or <50 mmHg), percutaneous oxygen saturation (SpO2<92%)
•11. Specific musculoskeletal limitations (arthritis, joint swelling, or conditions that limit walking or daily activities)
•12. Three or more falls in the past year: risk level II or higher in the Gifu University Fall Assessment.

发起方

Shimizu Masahito